Journal of the American Pharmacists Association : JAPhA
-
J Am Pharm Assoc (2003) · Jan 2020
Successful deprescribing of unnecessary proton pump inhibitors in a primary care clinic.
The objective of this study was to determine the rate of successful deprescribing of unnecessary proton pump inhibitors (PPIs) after implementation of a clinical pharmacist- managed program that included detailed tapering instructions, patient education, and follow-up. ⋯ Deprescribing long-term PPI therapy can be successful in a family medicine clinic when implementing a clinical pharmacist-managed program that includes detailed tapering instructions, patient education, and follow-up.
-
J Am Pharm Assoc (2003) · Jan 2020
Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose.
To describe the implementation of a statewide pharmacy program called ONE Rx (Opioid and Naloxone Education) within community pharmacies. ⋯ A statewide program to screen for opioid misuse and accidental overdose was successfully implemented.
-
J Am Pharm Assoc (2003) · Jan 2020
Effect of cannabis on opioid use in patients with cancer receiving palliative care.
Opioids are the primary therapy for cancer-related pain in patients receiving palliative care. More states are legalizing medical cannabis, which may provide a pain management alternative for some of these patients. This study aimed to estimate the effect of cannabis on opioid use in patients with cancer receiving palliative care. ⋯ A possibly meaningful difference in MEDD increase was seen when comparing the opioid monotherapy group with the opioid plus cannabis group. However, the study was not powered to test this hypothesis; the findings suggest that further research is warranted to determine the impact of cannabis use on opioid dosing in patients receiving palliative care for cancer.
-
J Am Pharm Assoc (2003) · Nov 2019
Evaluation of a pharmacist-led naloxone coprescribing program in primary care.
To determine the impact of a pharmacist-led coprescribing initiative on patient access to naloxone in a primary care setting. ⋯ Embedded clinical pharmacists in primary care have the potential to increase naloxone coprescribing for high-risk patients treated with chronic opioid therapy for pain.
-
J Am Pharm Assoc (2003) · Nov 2019
Drug discount cards in an era of higher prescription drug prices: A retrospective population-based study.
Drug discount programs have emerged as a potential option for patients seeking greater accessibility and affordability. However, there is limited knowledge regarding program utilization and cost savings. The objective of this study was to evaluate medication prescriptions with drug discount card usage and estimate cost savings. ⋯ The use of a drug discount program over 8 years resulted in total savings of nearly $200 million (approximately $18 per prescription) compared with the original cost. However, although patients might accrue financial benefit, there is still a lack of price transparency. Additional research is needed to better understand the impact of these programs and to evaluate ways to improve medication access at a reasonable cost to patients.